Promis Neurosciences Inc (PMN)

11:15 AM

ProMIS Neurosciences (NASDAQ:PMN) Now Covered by Maxim Group - Defense World

11:15 AM

02:16 AM

ProMIS Neurosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

02:16 AM

May 12, 2025

ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 12, 2025

May 12, 2025

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - Benzinga

May 12, 2025

May 12, 2025

ProMIS Neurosciences (PMN): Maxim Group Initiates Coverage with Buy Rating | PMN Stock News - GuruFocus

May 12, 2025

May 12, 2025

Maxim Group Initiates Coverage of ProMIS Neurosciences (PMN) with Buy Recommendation - Nasdaq

May 12, 2025

May 12, 2025

ProMIS Neurosciences Announces First Quarter 2025 Financial Resu - GuruFocus

May 12, 2025

May 12, 2025

ProMIS Neurosciences (PMN) Advances Alzheimer's Clinical Program - GuruFocus

May 12, 2025

May 12, 2025

ProMIS Neurosciences Inc. SEC 10-Q Report - TradingView

May 12, 2025

May 12, 2025

ProMIS Neurosciences Announces First Quarter 2025 Financial Results - GlobeNewswire

May 12, 2025

Apr 26, 2025

Multiple System Atrophy Treatment Algorithm, Clinical Trials - openPR.com

Apr 26, 2025

Apr 17, 2025

Parkinson’s vaccine selectively targets pathogenic αSyn - BioWorld MedTech

Apr 17, 2025

Apr 04, 2025

ProMIS Neurosciences stock hits 52-week low at $0.62 By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 04, 2025

ProMIS Neurosciences stock hits 52-week low at $0.62 - Investing.com India

Apr 04, 2025

Apr 04, 2025

Promis Neurosciences chief scientific officer buys $14,595 in shares - MSN

Apr 04, 2025

Apr 02, 2025

ProMIS Neurosciences’ (PMN) Buy Rating Reaffirmed at Guggenheim - Defense World

Apr 02, 2025

Apr 01, 2025

ProMIS Neurosciences Reports 2024 Financial Turnaround - TipRanks

Apr 01, 2025

Mar 31, 2025

ProMIS Neurosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025

Mar 31, 2025

PROMIS NEUROSCIENCES Earnings Results: $PMN Reports Quarterly Earnings - Nasdaq

Mar 31, 2025

Mar 31, 2025

ProMIS Neurosciences Inc. (PMN) reports earnings - Quartz

Mar 31, 2025

Mar 31, 2025

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights - The Manila Times

Mar 31, 2025

Mar 31, 2025

Form 424B5 ProMIS Neurosciences - StreetInsider

Mar 31, 2025

Mar 31, 2025

ProMIS Neurosciences Inc. SEC 10-K Report - TradingView

Mar 31, 2025

Mar 28, 2025

ProMIS Neurosciences Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView

Mar 28, 2025

Mar 25, 2025

ProMIS to present neurodegenerative disease research By Investing.com - Investing.com Australia

Mar 25, 2025

Mar 24, 2025

New Diagnostics And Treatments Transform Neurodegenerative Disease Care - Evrim Ağacı

Mar 24, 2025

Mar 24, 2025

ProMIS to present neurodegenerative disease research - Investing.com India

Mar 24, 2025

Mar 24, 2025

ProMIS Neurosciences Showcases Preclinical Data on - GlobeNewswire

Mar 24, 2025

Mar 24, 2025

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference - Yahoo Finance

Mar 24, 2025

Mar 23, 2025

ProMIS Neurosciences (PMN) Expected to Announce Quarterly Earnings on Monday - Defense World

Mar 23, 2025

Mar 20, 2025

Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Ionis Pharma - Barchart

Mar 20, 2025

Mar 20, 2025

Multiple System Atrophy Market to Reach New Heights in Growth - openPR

Mar 20, 2025

Mar 13, 2025

ProMIS to present vaccine data at neurology meeting By Investing.com - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

ProMIS to present vaccine data at neurology meeting - Investing.com India

Mar 13, 2025

Mar 13, 2025

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting - The Manila Times

Mar 13, 2025

Mar 13, 2025

ProMIS Neurosciences to Present Preclinical Data on Computational Vaccine Development for Neurodegenerative Diseases at AAN Annual Meeting - Nasdaq

Mar 13, 2025

Mar 13, 2025

ProMIS Neurosciences Showcases Preclinical Data on Platform - GlobeNewswire

Mar 13, 2025

Mar 12, 2025

PROMIS NEUROSCIENCES Earnings Preview: Recent $PMN Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 12, 2025

Mar 11, 2025

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference - GlobeNewswire

Mar 11, 2025

Mar 01, 2025

ProMIS Neurosciences’ (PMN) “Buy” Rating Reiterated at Guggenheim - Defense World

Mar 01, 2025

Feb 25, 2025

ProMIS Neurosciences begins Alzheimer’s trial dosing - Investing.com India

Feb 25, 2025

Feb 25, 2025

ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial - TipRanks

Feb 25, 2025

Feb 25, 2025

GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement - The Manila Times

Feb 25, 2025

Feb 25, 2025

ProMIS Neurosciences begins Alzheimer’s trial dosing By Investing.com - Investing.com South Africa

Feb 25, 2025

Feb 25, 2025

ProMIS Neurosciences begins Alzheimer's trial dosing - Investing.com

Feb 25, 2025

Feb 25, 2025

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease - GlobeNewswire

Feb 25, 2025

Feb 25, 2025

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for ... - The Bakersfield Californian

Feb 25, 2025